This is the first book to bring together the extensive pharmacological, preclinical, and clinical studies that have been done in the United States and Europe on alpidem (Ananxyl), a new nonbenzodiazepine anxiolytic which, like the hypnotic agent zolpidem (Stilnox), belongs to the imidazopyridine family of drugs. The book presents original research articles on the receptors involved in the action of anxiolytics, particularly benzodiazepines; the selective action of alpidem on a specific subtype of receptors; the ...
Read More
This is the first book to bring together the extensive pharmacological, preclinical, and clinical studies that have been done in the United States and Europe on alpidem (Ananxyl), a new nonbenzodiazepine anxiolytic which, like the hypnotic agent zolpidem (Stilnox), belongs to the imidazopyridine family of drugs. The book presents original research articles on the receptors involved in the action of anxiolytics, particularly benzodiazepines; the selective action of alpidem on a specific subtype of receptors; the psychopharmacological profile of alpidem; its safety; and the clinical experience with alpidem for treatment of anxiety disorders. The findings indicate that alpidem has an efficacy similar to benzodiazepines; and that, because of its more selective receptor activity, it is less likely to impair memory or induce tolerance and dependence. Several contributors analyze the diverse GABA receptors modulatory sites involved in the action of anxiolytics and identify new targets for anxioselective drugs.
Read Less
Add this copy of Imidazopyridines in Anxiety Disorders: a Novel to cart. $59.99, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 1993 by Raven Pr.
